Kite, a Gilead Company, and Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, announced on August 05th a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bio’s ACUA technology platform for allogeneic cell therapy. Founded in 2020, Appia Bio recently announced the completion of its Series A financing to support the advancement of the company’s pipeline of allogeneic CAR-iNKT cell therapy candidates into the clinic. With its ACUA technology platform, Appia Bio leverages the biology of lymphocyte development to generate CAR-iNKT cells from HSCs. The ACUA platform offers the potential for improved efficacy and safety, streamlined manufacturing, and off-the-shelf accessibility of HSC-derived CAR iNKT-cell therapies.
For further information, see Gilead (https://investors.gilead.com/news-releases/news-release-details/kite-and-appia-bio-announce-collaboration-research-and-develop)